Drug Profile
Research programme: triptolide derivatives - Pharmagenesis
Alternative Names: WilGrafLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pharmagenesis
- Developer Astellas Pharma; Pharmagenesis
- Class Diterpenes
- Mechanism of Action Dinoprostone receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Skin disorders; Transplant rejection
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Transplant-rejection in USA (PO)